Bosutinib (As Monohydrate)
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Bosutinib (As Monohydrate) |
| DrugBank ID | DB06616 |
| Brand Names (EU) | Bosulif |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.75% |
Approved Indication (EMA)
Bosulif is indicated for the treatment of:• Adult and paediatric patients aged 6 years and older with newly-diagnosed (ND) chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).• Adult and paediatric patients aged 6 years and older with CP Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.• Adult patients with accelerated phase (AP)
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | myeloid leukemia | 98.75% | DL |
| 2 | thrombocytopenia | 98.62% | DL |
| 3 | marcothrombocytopenia with mitral valve insufficiency | 98.46% | DL |
| 4 | hereditary thrombocytopenia with normal platelets | 98.45% | DL |
| 5 | transient neonatal thrombocytopenia | 98.34% | DL |
| 6 | dense granule disease | 98.31% | DL |
| 7 | platelet storage pool deficiency | 97.43% | DL |
| 8 | plasma cell myeloma | 96.82% | DL |
| 9 | HER2 positive breast carcinoma | 96.72% | DL |
| 10 | indolent plasma cell myeloma | 96.47% | DL |
| 11 | thrombotic disease | 96.08% | DL |
| 12 | female breast carcinoma | 96.05% | DL |
| 13 | primary cutaneous T-cell lymphoma | 95.63% | DL |
| 14 | malignant catarrh | 95.42% | DL |
| 15 | infectious bovine rhinotracheitis | 95.42% | DL |
| 16 | cytomegalovirus infection | 95.36% | DL |
| 17 | progesterone-receptor negative breast cancer | 95.34% | DL |
| 18 | progesterone-receptor positive breast cancer | 95.21% | DL |
| 19 | normal breast-like subtype of breast carcinoma | 95.21% | DL |
| 20 | breast tumor luminal A or B | 95.14% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.